Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1023578512 | 10235785 | 12 | F | 20160801 | 20140613 | 20160812 | EXP | NO-PFIZER INC-2014156420 | PFIZER | LAURITZSEN G. HIGH 7 YEAR-SURVIVAL RATES IN ADULT LYMPHOBLASTIC LYMPHOMA AFTER TREATMENT WITH A NORWEGIAN INTENSIFIED ALL INDUCTION, HIGH-DOSE BEAM, AUTOLOGOUS STEM CELL SUPPORT AND MEDIASTINAL RATIATION THERAPY. HAEMATOLOGICA. 2012;97 (S1):183 | 46.00 | YR | M | Y | 0.00000 | 20160812 | OT | NO | NO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1023578512 | 10235785 | 1 | PS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous (not otherwise specified) | 1.5 MG/M2, MAX 2.0 MG (DAYS 1, 8, 15, 22, AND 29) | 71484 | 1.5 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 2 | SS | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | 200 MG/M2,(DAYS 43-47) | 71868 | 200 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 3 | SS | CYTARABINE. | CYTARABINE | 1 | Intrathecal | 40 MG, (DAYS 78, 92, 106) | 71868 | 40 | MG | ||||||||
| 1023578512 | 10235785 | 4 | SS | DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 30 MG/M2, (DAYS 8, 15, AND 22) | 50467 | 30 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 5 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intrathecal | 15 MG, (DAYS 15, 29, 43, 64) | 11719 | 15 | MG | ||||||||
| 1023578512 | 10235785 | 6 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | 1500 MG/M2,(DAYS 64 AND 78) | 11719 | 1500 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 7 | SS | DAUNORUBICIN | DAUNORUBICIN | 1 | Intravenous (not otherwise specified) | 50 MG/M2,(DAYS 43, 45, AND 47) | 0 | 50 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 8 | SS | MERCAPTOPURINE. | MERCAPTOPURINE | 1 | Intravenous (not otherwise specified) | 35 MG/M2, (DAYS 64-111) | 0 | 35 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 9 | SS | L-ASPARAGINASE | ASPARAGINASE | 1 | Intravenous (not otherwise specified) | 10000 IU, (DAYS 8-21) | 0 | 10000 | IU | ||||||||
| 1023578512 | 10235785 | 10 | SS | THIOGUANINE | THIOGUANINE | 1 | Intravenous (not otherwise specified) | 150 MG/M2, (DAYS 43-47) | 0 | 150 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 11 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 750 MG/M2,(DAYS 15, 22, AND 29) | 0 | 750 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 12 | SS | G-CSF | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | 10 MCG/KG/DAY | 0 | |||||||||||
| 1023578512 | 10235785 | 13 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 40 MG/M2, (DAY 1-29, TAPER TO DAY 35) | 0 | 40 | MG/M**2 | ||||||||
| 1023578512 | 10235785 | 14 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Intrathecal | 10 MG, UNK | 0 | 10 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 1023578512 | 10235785 | 1 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 2 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 4 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 5 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 7 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 8 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 9 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 10 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 11 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 1023578512 | 10235785 | 12 | Peripheral blood stem cell apheresis |
| 1023578512 | 10235785 | 13 | Precursor T-lymphoblastic lymphoma/leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 1023578512 | 10235785 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 1023578512 | 10235785 | Multiple organ dysfunction syndrome | |
| 1023578512 | 10235785 | Venoocclusive disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |